H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $10
Sangamo Therapeutics Analyst Ratings
TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating
Truist Financial Upgrades Sangamo Therapeutics(SGMO.US) to Buy Rating, Announces Target Price $7
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $10
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Is Maintained at Overweight by Barclays
Sangamo Therapeutics Analyst Ratings
TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $10
A Quick Look at Today's Ratings for Sangamo Therapeutics(SGMO.US), With a Forecast Between $3 to $10
Wells Fargo Gives a Hold Rating to Sangamo Biosciences (SGMO)
Sangamo Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Raises Target Price to $10
Truist Financial Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating
TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating
A Quick Look at Today's Ratings for Sangamo Therapeutics(SGMO.US), With a Forecast Between $1 to $5
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5